Jasper Therapeutics (NASDAQ:JSPRW – Get Free Report) is projected to post its results before the market opens on Tuesday, March 10th. Analysts expect Jasper Therapeutics to post earnings of ($0.6689) per share for the quarter.
Jasper Therapeutics Stock Performance
JSPRW opened at $0.02 on Friday. Jasper Therapeutics has a 52 week low of $0.02 and a 52 week high of $0.18. The business has a 50 day moving average of $0.04 and a 200-day moving average of $0.08.
Jasper Therapeutics Company Profile
Jasper Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.
The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells.
Read More
- Five stocks we like better than Jasper Therapeutics
- “I just bought 10,000 shares of a $5 stock…”
- 3 Signs You May Want to Switch Financial Advisors
- How JPMorgan’s $8,000 Gold Call Will Leave Most Retirement Accounts Behind
- Silver Is the New Oil—And the World’s Running Dry
- Central banks just did something they haven’t done since 1967
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
